A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab

PURPOSE: This first-in-human study was designed to evaluate the pharmacokinetic (PK) equivalence between HD204 and the European Union (EU)-sourced bevacizumab, between HD204 and the United States of America (US)-sourced bevacizumab, and between EU-sourced and US-sourced bevacizumab (NCT 03390673). M...

Descripción completa

Detalles Bibliográficos
Autores principales: Demarchi, Martin, Coliat, Pierre, Barthelemy, Philippe, Schott, Roland, BenAbdelghani, Meher, Kim, Michael, Hii, Jocelyn Chung Shii, Feyaerts, Peggy, Ang, Felicia Rui Xia, Derde, Marie Paule, Deforce, Filip, Petit, Thierry, Schwabe, Chris, Wynne, Chris, Park, Lisa Soyeon, Pivot, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460034/
https://www.ncbi.nlm.nih.gov/pubmed/34555031
http://dx.doi.org/10.1371/journal.pone.0248222

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460034/
https://www.ncbi.nlm.nih.gov/pubmed/34555031
http://dx.doi.org/10.1371/journal.pone.0248222

Ejemplares similares